Trokendi XR Capsules (Supernus) – Superpotent Drug Issue (2016)
Class II: A situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Class II recall indicates potential for temporary health effects.
This AI-generated summary is provided for general informational purposes only and is derived from publicly available recall notices. It supplements but does not replace official agency classifications or safety instructions.
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
Trokendi XR (topiramate) extended-release capsule, 50mg, 30-count blister pack, Rx only, Manufactured by: Catalent Pharma Solutions, Winchester, KY 40391, Manufactured for: Supernus Pharmaceuticals, Inc., Rockville, MD 20850, NDC 17772-102-15
Brand
Supernus Pharmaceuticals, Inc.
Lot Codes / Batch Numbers
Lot # 426636, Exp 4/22/18
Products Sold
Lot # 426636, Exp 4/22/18
Supernus Pharmaceuticals, Inc. is recalling Trokendi XR (topiramate) extended-release capsule, 50mg, 30-count blister pack, Rx only, Manufacture due to Superpotent Drug: Failure of assay specifications in the capsule.. This is a Class I recall, indicating a high risk of serious health consequences. Based on FDA drug enforcement report.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
Superpotent Drug: Failure of assay specifications in the capsule.
Recommended Action
Per FDA guidance
Consumers should stop using the product and contact the recalling firm, their healthcare provider, or return it to the place of purchase.
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticePage updated: Jan 7, 2026